Stem Cell Clinic

BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.7 Million Grant From Israel’s Office of the Chief Scientist

By Stem Cell Medical Center

We thank the Israel Office of the Chief Scientist for their commitment to innovation and their continuing support of our development of a cell therapy based treatment for a major disease of aging, said Charles Irving, PhD, Chief Executive Officer of Cell Cure.

I join with Dr. Irving in thanking the OCS for their generous support in acclerating pluripotent stem cell research into clinical applications, said Benjamin Reubinoff, MD, PhD, Chief Scientific Officer of Cell Cure and Chairman of Obstetrics and Gynecology and Director of the Hadassah Human Embryonic Stem Cell Research Center at Hadassah University Medical Center, Jerusalem, Israel. The dry form of age-related macular degeneration afflicts over seven million people in the United States alone. We anticipate that OpRegen will make a real difference in the quality of life of the aging baby-boomer generation afflicted with this condition in many industrialized countries.

The OCS has previously provided grants to Cell Cure. Cell Cure will pay a royalty to the OCS on revenues from OpRegen until total royalties paid equal 100% of the amount of the grant plus interest at a LIBOR rate. Historically, Cell Cure Neurosciences or BioTimes other subsidiaries have raised capital, received grants, or generated revenues independently ofBioTimeto help fund their operations. We expect Cell Cure Neurosciences to continue to pursue such financing strategies in the future.

About the Office of the Chief Scientist

The Office of the Chief Scientist in the Ministry of Industry, Trade and Labor is charged with the execution of government policy for the support of industrial R&D.The goal of the OCS is to assist in the development of technology in Israel as a means of fostering economic growth, encouraging technological innovation and entrepreneurship, leveraging Israels scientific potential, enhancing the knowledge base of industry in Israel, stimulating high value-added R&D, and encouraging R&D collaboration both nationally and internationally. A variety of ongoing support programs developed and offered by the OCS play a major role in enabling Israel to be a key center for high-tech entrepreneurship.

About Cell Cure Neurosciences Ltd.

Cell Cure Neurosciences Ltd. was established in 2005 as a subsidiary of ES Cell International Pte. Ltd. (ESI), now a subsidiary of BioTime, Inc. (NYSE MKT: BTX). Cell Cure is located in Jerusalem, Israel on the campus of Hadassah University Hospital. Cell Cure's mission is to become a leading supplier of human cell-based therapies for the treatment of retinal and neural degenerative diseases. Its technology platform is based on the manufacture of diverse cell products sourced from clinical-grade (GMP) human embryonic stem cells. Its current focus is the development of retinal pigment epithelial (RPE) cells for the treatment of age-related macular degeneration. Cell Cure's major shareholders include BioTime, Inc., Hadasit BioHoldings Ltd. (Tel Aviv Stock Exchange: HDST), and Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA). Additional information about Cell Cure can be found on the web at http://www.cellcureneurosciences.com. A video of a presentation by Cell Cures CEO Dr. Charles Irving is available on BioTimes web site.

About BioTime, Inc.

BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. BioTimes focus is on pluripotent stem cell technology based on human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTimes therapeutic and research products include a wide array of proprietary PureStem progenitors, HyStem hydrogels, culture media, and differentiation kits. BioTime is developing Renevia (a HyStem product) as a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. In addition, BioTime has developed Hextend, a blood plasma volume expander for use in surgery, emergency trauma treatment and other applications. Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive licensing agreements.

BioTime is also developing stem cell and other products for research, therapeutic, and diagnostic use through its subsidiaries:

View original post here:
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.7 Million Grant From Israel’s Office of the Chief Scientist

Day 2 Doing exercise Katrina has to keep healthy to do stem cell treatment that will save her life. – Video

By Stem Cell Treatment


Day 2 Doing exercise Katrina has to keep healthy to do stem cell treatment that will save her life.
Katrina Brown was a British army nurse who has served in Iraq and Afghanistan. Whilst in Iraq she was exposed to Depleted Uranium and this has caused her to ...

By: Katrinas Future

Go here to see the original:
Day 2 Doing exercise Katrina has to keep healthy to do stem cell treatment that will save her life. - Video

BCRO (Stem) Cell Transplants as Treatment For Incurable and …

By Stem Cell Treatment

What To Do To Get BCRO Fetal Precursor (Stem) Cell Transplantation Treatment

A/ You Cannot Get BCRO Fetal Precursor (Stem) Cell Transplantation Without a Physician Trained In This Therapeutic Method...

...and unless you have, or know of, a hospital, a clinic, or a physician, performing BCRO fetal precursor (stem) cell transplantation already, you will have to find one.

We can help you in that. Click here for the list of clinics that use BCRO's fetal precursor (stem) cell transplants and wished to be listed..

If you decide to get your fetal precursor (stem) cell transplantation at one of the above clinics , then you can skip reading the rest of this homepage.

If your physician is familiar with BCRO fetal precursor (stem) cell transplantation, and willing to study pertinent data on this web site and on Internet by opening PUBMED, the computerized medical data base of MEDLINE, U.S. National Library of Medicine, by clicking on one of ten KEYWORDS (if you click on the "KEYWORDS" link, you will get to all ten keywords on our Homepage),

then your physician should write a prescription for preparation of your fetal precursor (stem) cell transplants by our company, and handle the implantation for you.

("Stem Cell Transplantation, a Textbook of Stem Cell Xeno-transplantation" by E. Michael Molnar, M.D., was published by a Medical and Engineering Publishers, Inc., Washington, D.C., in February 2006, the first textbook of this subject in the world for medical professionals and students. Click on http://www.mepublishers.com On the same web site you can can find the latest book by the same author: 'Treatment of Incurable and Untreatable Diseases', published for general readership by the same publisher in November 2012.")

If your physician would not write such a prescription for you, and you made a decision that BCRO (stem) cell transplantation is necessary for treatment of whatever medical condition(s) you suffer from, then it is better to consult one of the clinics or one of our medical experts instead.

Follow this link:
BCRO (Stem) Cell Transplants as Treatment For Incurable and ...

MEDISTEM PURCHASED BY INTREXON

By Stem Cell Treatment

By Bradley J. Fikes U-T 12:01 a.m.Dec. 24, 2013

Medistem, a San Diego-based developer of stem cell treatments, has been purchased for about $26 million by biotech Intrexon Corp. of Germantown, Md.

Intrexon will use its genetic engineering technology to increase the potency of Medistems stem cells, said Alan Lewis, Medistems chief executive. The sale, announced Friday, is expected to be completed by the first quarter.

Medistem says its stem cells can form new blood vessels, reduce inflammation and could treat diseases such as diabetes and cardiovascular disease.

These adult stem cells are unusually versatile and can be used in unrelated patients, making them a universal donor kind of stem cell, Lewis said. Derived from the uterine lining, they are called endometrial regenerative cells.

Medistem is a small company, with just a handful of employees. Lewis said he and some others from the company will be taken on by Intrexon, although exact details have yet to be specified.

In January 2012, Medistem began a clinical trial of its cells in Russia in patients with congestive heart failure. The company has done preclinical studies in the United States for a diabetes treatment. Intrexon is developing synthetic biology technology for use in health, food and environmental applications, similar to the goals of genomics pioneer Craig Venter, Lewis said.

Medistems cells will extend Intrexons reach in health care, giving Intrexon the ability to make clinical-grade stem cells, said Samuel Broder, senior vice president of Intrexons health division, in a statement. The division is located in San Diego.

Medistem developed its stem cells as a source of transplantable tissues. Broder said Intrexons technology could also be used to engineer the stem cells to produce protein and RNA-based drugs.

In another announcement last week, Intrexon said it had hired Gregory Frost, CEO of San Diego-based Halozyme, to head its health sector.

See the original post here:
MEDISTEM PURCHASED BY INTREXON

‘I will walk.’ Kim Dennie’s journey of hope brings her closer to goal

By Stem Cell Treatment

Niagara This Week - St. Catharines

THOROLD -- Following a month-long stay in China, Kim Dennie has more faith now than she ever did that her wheelchair will be a part of her past.

On Jan. 13, Dennie left her home in Allanburg on a journey to China for stem cell therapy treatments not available in Canada. After an assessment, Dennie was told the words she has so longed to hear since her life was changed nearly four years ago.

"They told me that my condition is not that bad and I should be able to walk again," Dennie told This Week. "With the right mindset and persistence and continued therapy, I will walk."

In July 2003 Dennie, and her two children, 13-year-old Brittany and 12-year-old Jamie, were returning from a trip to Sudbury. The car she was riding in was broadsided by an oncoming vehicle. The car slammed into the passenger side door where she was sitting. Dennie broke her back, neck, shoulder and pelvis and hasn't been able to walk since.

The initial diagnosis was complete spinal chord injury, leaving her paralyzed from the waist down.

Three months later she was wiggling the toes on her left foot and the diagnosis was changed from complete to an incomplete spinal cord injury. Since that day, Dennie has vowed to herself that she will walk away from the wheelchair she has come to rely on.

She heard about the treatment from a friend she met in therapy and immediately knew it was something worth trying.

Dennie had four rounds of stem cell injection into her spinal chord and another which ran through an IV in her hand. Following the first treatment she saw no changes, but after the second her spasms decreased, her neurological burning pain decreased and she started to regain movement in her right leg.

"I've regained quite a bit of mobility," a beaming Dennie said. "I can sit on the edge of my bed with my leg hanging over it and can lift it back up. I couldn't do any of that before I left."

Read the original:
'I will walk.' Kim Dennie's journey of hope brings her closer to goal

Knoepfler Lab Stem Cell Blog | Building stem cell bridges

By Stem Cell Medicine

Reading these one doesn't know whether to laugh or cry they are so stupid. "Top researcher: iPS cells probably already embryos".This article was so wrong about so many things that it gives dumb a bad name. "Adventurous woman sought to carry Neanderthal baby". Who needs the National Enquirer? "Dana White media scrum: Meniere's disease cured by stem cell treatment inGermany". Stem cells are like throwing disease against the cage? "Op-Ed: Stem cell derived anti-aging cream is on its way, and it works". Really? Wow, I can't believe it. "Bushs belated victory: Pro-life groups celebrate ethical shift in stem cell research." Uh, no. Bush does not deserve credit for iPS READ MORE [...] Every year I do predictions for the stem cell field for the coming year. You can see my full post on my predictions for this year here. Stay tuned soon for my predictions for 2014. How'd I do for 2013 with my predications? Each prediction for this year that I made last year is bolded and my assessment now of how I did for each is in green or red.I did reasonably well for 2013. Sometimes predictions get mixed in with what hopes or thinks would be the best thing to happen not necessarily the most likely. 10. At least two new lawsuits are filed against stem cell businesses, most likely by patients.I think the number is more likely to be 3-4, but lets see what develops. RIGHT. READ MORE [...] Take Our Poll

Id like to learn more about who reads this blog. Please take the above poll. Use your judgment to pick a single category that best describes you. I realize some folks may fit into more than one category.

Thanks

Paul

Read more:
Knoepfler Lab Stem Cell Blog | Building stem cell bridges

FRONTLINE CANCER: Working to eliminate the cancer stem cells that sustain disease

By Stem Cell Medical Center

By Scott M. Lippman

Chemotherapies seek out cancer cells by targeting a fundamental characteristic of cancer cells: their rapid and frequent replication. But in doing so, these drugs can destroy healthy cells that also grow quickly. The result: adverse effects like hair loss and nausea.Worse, the benefits of chemotherapy are frequently short-lived. Seemingly beaten by chemotherapy, a cancer can suddenly return, spreading from its original site to other parts of the body with often catastrophic consequences. Ninety percent of cancer-related deaths are due to metastasis, and almost every cancer can be metastatic.

Why do cancers recur when therapeutic evidence suggests theyve been wiped out? The answer lies in a type of cancer cell with the powerful characteristic of normal stem cells the ability to self-renew or regenerate.

Sott M. Lippman, M.D.

Unlike normal stem cells, however, this ability in cancer stem cells does not turn off.

Cancer stem cells are a relatively new phenomenon to cancer science. Conclusive evidence of their existence was found only in 1994, though in the years since, extraordinary efforts have been made to better understand them in order to destroy them.

Its a daunting task. Cancer stem cells persist in small communities, often tucked away in the deep recesses of bone. They do not divide with dangerous abandon, which would make them easier targets of chemotherapy. In fact, they often lie dormant, essentially invisible until they begin again the process of self-renewal, differentiation and cancer relapse.

Toughest of all, they are very hard to kill, quickly developing resistance to existing drug therapies.

Nonetheless, progress is being made, some of it driven by researchers at UC San Diego Moores Cancer Center. Among them is Catriona Jamieson, M.D., Ph.D., an associate professor of medicine in the UC San Diego School of Medicine and director of Stem Cell Research at Moores Cancer Center.

Jamieson has devoted much of her career to deciphering the secrets of cancer stem cells and, more importantly, working to develop effective treatments to rid the body of them. She specializes in myeloproliferative neoplasms (MPNs) and leukemia.

See the rest here:
FRONTLINE CANCER: Working to eliminate the cancer stem cells that sustain disease

Opinions on Stem Cell Facelift? Doctor Answers, Tips

By Stem Cell Doctors

many plastic surgeons who perform structural fat grafting report that patients often describe a variety of improvements in their facial skin following fat grafting surgery. This observation has led to the use of fat grafting in reconstructive surgery, for instance in the management of chronic wounds such as those seen in some patients following radiation treatment for cancer. Fat grafting into the tissues below a chronic, non-healing wound has been shown to stimulate successful wound healing in a number of studies.

So what is responsible for this effect? Many of us suspect that it is produced by 'stem cells' which are known to be present in abundance in human adipose (fatty) tissue. Stem cells are very dynamic human cells which have the capacity to be transformed into any number of cell types (fat, muscle, skin, fascia, etc), and which are capable of producing a variety of proteins which promote the repair of damaged cells and tissues.

Much of the evidence has been anecdotal, i.e. the personal observations of physicians made while treating patients in their usual clinical practice, outside the setting of a specific scientific study. A great deal of basic science research is now being done to specifically determine cause and effect, and it is certain that over the next few years we will gain a much clearer understanding of the healing properties of fatty tissue and stem cells.

Be aware that the term 'stem cell' is increasingly being used in what I feel may be an irresponsible manner - as a marketing gimmick to attract patients to a particular practice or surgeon. Nobody has an exclusive claim or right to the use of stem cells, and as yet no one has demonstrated an objective, quantitative method for measuring any 'stem cell effect' in facial rejuvenation surgery, if it is truly present. I believe that this effect exists, but it currently is not objectively and reproducibly measurable and therefore should not be used to 'sell' surgery.

Web reference: http://www.michaellawmd.com

View original post here:
Opinions on Stem Cell Facelift? Doctor Answers, Tips

Research – Stem Cell Biology and Regenerative Medicine …

By Stem Cell Medicine

Every one of us completely regenerates our own skin every 7 days. A cut heals itself and disappears in a week or two. Every single cell in our skeleton is replaced every 7 years.

The future of medicine lies in understanding how the body creates itself out of a single cell and the mechanisms by which it renews itself throughout life.

When we achieve this goal, we will be able to replace damaged tissues and help the body regenerate itself, potentially curing or easing the suffering of those afflicted by disorders like heart disease, Alzheimers, Parkinsons, diabetes, spinal cord injury and cancer.

Research at the institute leverages Stanfords many strengths in a way that promotes that goal. The institute brings together experts from a wide range of scientific and medical fields to create a fertile, multidisciplinary research environment.

There are four major research areas of emphasis at the institute:

Theres no way to know, beforehand, which particular avenue of stem cell research will most expediently yield a successful treatment or cure. Therefore, we need to vigorously pursue a broad number of promising leads concurrently.

--Philip A. Pizzo, MD Carl and Elizabeth Naumann Professor Dean, Stanford University School of Medicine

View post:
Research - Stem Cell Biology and Regenerative Medicine ...

Discovery of Lung Stem Cell Offers New Hope for COPD Treatment

By Stem Cell Medicine

Contrary to popular scientific belief, human lung stem cells do exist and their discovery may lead to improved treatments for COPD.

Dr. Piero Anversa, director of the Center for Regenerative Medicine at Brigham and Women's Hospital (BWH) in Boston, Massachusetts, and his colleagues believe that they have identified the first human lung stem cell. This discovery has the potential to repair and regenerate lung tissue in people suffering from COPD and other lung diseases. Dr. Anversa states: "The discovery of this stem cell has the potential to offer those who suffer from chronic lung diseases a totally novel treatment option by regenerating or repairing damaged areas of the lung."

How do lung stem cells operate? When placed in a culture medium, the newly discovered lung stem cells divide into new stem cells and also into cells that have the ability to form new lung structures such as alveoli, bronchioles and pulmonary blood vessels. This, my friends, is absolutely incredible!

Over the past several years, I have kept you up to date on stem cell research in the United States and other countries. As many of you may, or may not know, stem cell treatment with manipulation is currently not available here in the United States. It will be interesting to note how this new discovery will influence the decision on whether or not to legalize it, making it available to all who need it.

To read more about stem cell therapy, visit the following links:

Would you undergo stem cell therapy for COPD? If not, what would influence your decision? Please leave your comments and vote in the poll.

Source:

Piero Anversa, et. al. Evidence for Human Lung Stem Cells. New England Journal of Medicine, 2011; 364 (19): 1795-1806 DOI: 10.1056/NEJMoa1101324; published online 12 May 2011.

Sign up for my free newsletter! Follow me on Twitter or Facebook

Original post:
Discovery of Lung Stem Cell Offers New Hope for COPD Treatment

→←